Tinzaparin
149; do not use enoxaparin with any of the following medicines without first talking to your doctor: aspirin, ibuprofen motrin, advil, nuprin, and others ; , ketoprofen orudis kt, orudis, oruvail ; , naproxen aleve, naprosyn, anaprox, and others ; , indomethacin indocin ; , diclofenac cataflam, voltaren ; , diflunisal dolobid ; , etodolac lodine ; , fenoprofen nalfon ; , flurbiprofen ansaid ; , ketorolac toradol ; , nabumetone relafen ; , oxaprozin daypro ; , piroxicam feldene ; , sulindac clinoril ; , tolmetin tolectin ; , meloxicam mobic ; , or any other nonsteroidal anti-inflammatory medication; warfarin coumadin ardeparin normiflo ; , dalteparin fragmin ; , danaparoid orgaran ; , or tinzaparin innohep aspirin and dipyridamole aggrenox ticlopidine ticlid ; or clopidogrel plavix or dipyridamole persantine.
Half-life of the HN mutant in mice. Consistent with earlier studies in mice in which IgG mutants with reduced pH dependence for FcRn binding were assessed 3 ; , this mutant has short in vivo persistence relative to wild-type human IgG1, with a -phase half-life of 62.8 2.7 h HN ; that is significantly shorter than that of wild-type 250.6 15.3 h ; Fig. 2a ; . The short in vivo.
SUN SCREEN Sun Screens and Sun Blocks are Toxic and Cancer-Causing agents. The quickest way to skin cancer is NOT exposure to the sun, but the poisonous chemicals in sun block that penetrate.
Knowledge of mental items is demon-proof, knowledge of the items to which they correspond is demon-proof, has roots at least as far back as John Locke. Thus Locke not only acknowledges that his theory of simple ideas has this consequence, though he would no doubt have expressed it differently, he actually takes it as a point in favour of his theory. He invokes the allegedly unsavoury consequence as providing the solution to a problem about knowledge of the external world. Locke writes, 3 How shall the Mind, when it perceives nothing but its own Ideas, know that they agree with Things themselves? This, though it seems not want to difficulty, yet, I think there be two sorts of Ideas, that, we may be assured, agree with Things. 4. First, The first are simple Ideas, which since the Mind, as has been shewed, can by no means make to it self, must necessarily be the product of Things operating on the Mind in a natural way, Thus the Idea of Whiteness, or Bitterness, . has all the real conformity it can, or ought to have, with Things without us. And this conformity between our simple Ideas, and the existence of Things, is sufficient for real Knowledge. Locke, 1689 Book IV, Chapter IV, original emphasis.
Months of coumadin. Six-month follow-up of these patients demonstrated no significant difference in recurrent thrombosis or major bleeding complications.11 These initial studies using low molecular weight heparin in the treatment of deep venous thrombosis were conducted with tinzaparin and nadroparin, formulations of low molecular weight heparin not currently available in the United States. However, similar early results also were achieved with fixed-dose enoxaparin.12 Moreover, clinical trials examining the use of danaparoid13 and ardeparin, 14 both of which are available in the United States, indicated that these compounds could be used for the treatment of venous thromboembolism as well, potentially giving clinicians a broad range of treatment options. In 1996, 2 seminal studies examining the use of low molecular weight heparin for home treatment of deep venous thrombosis were published simultaneously. In the first study, Levine et al identified 500 patients with deep venous thrombosis and randomly assigned them to receive either unfractionated heparin in a hospital setting or enoxaparin 1 mg kg twice daily at home.15 The rates of recurrent thromboembolism and major bleeding complications were equivalent in both groups. The great difference in therapy was demonstrated not in clinical efficacy, but length of hospital stay. Patients who received unfractionated heparin spent an average of 6.5 days in the hospital; those who received low molecular weight heparin spent an average of 1.1 days in the hospital. Moreover, 120 of 247 of patients randomized to receive low molecular weight heparin were never hospitalized. In the second study, Koopman et al identified 400 patients with deep venous thrombosis, and similarly randomized them to receive unfractionated heparin in a hospital setting or low molecular weight heparin in this case, nadroparin ; .16 The patients assigned to receive nadroparin were permitted to complete their therapy at home as soon as it was thought to be appropriate. Of these patients, 36% were never hospitalized and 40% were discharged early, resulting in an average 67% reduction in length of stay. The rates of recurrent thromboembolism and major bleeding complications were statistically equivalent in the nadroparin and unfractionated heparin groups. Moreover, physical activity and social functioning were better in the group assigned to receive low molecular weight heparin. While the Koopman and Levine studies confirmed that outpatient low molecular weight heparin, under certain circumstances, can be as safe and effective as inpatient unfractionated heparin in the treatment of deep venous thrombosis, three meta-analyses suggest that low molecular weight heparin may in fact be clinically superior to unfractionated heparin. A meta-analysis of 10 separate studies published between 1984 and 1994 using low molecular weight heparin in the treatment deep venous thrombosis indicated that low molecular weight heparin compared with unfractionated heparin ; resulted in a 68% reduction in the relative risk of clinically significant bleeding, a 53% reduction in the relative risk of symptomatic thromboembolic complications, and a 47% reduction in the relative risk of mortality.17 This analysis was largely dependent on three studies using nadroparin and tinzaparin. A second meta-analysis that specifically compared fixeddose subcutaneous low molecular weight heparin with unfractionated heparin either intravenous or subcutaneous ; in the treatment of venous thromboembolic disease concluded that low molecular weight heparin was as effective as unfractionated heparin in preventing recurrence and significantly reduced major hemorrhage odds ratio [OR] 0.55 ; and overall mortality OR 0.74 ; .18 A third meta-analysis that examined 11 studies published between 1991 and 1997 comparing low molecular weight heparin with unfractionated heparin in the treatment of deep venous thrombosis concluded that low molecular weight heparin was associated with decreased mortality OR 0.71 ; , but statistically equivalent rates of major bleeding complications and recurrence.19 These meta-analyses suggest that low molecular weight heparin is not only safe and effective for the treatment of venous thromboembolic disease, but may be superior to the traditional approach using unfractionated heparin.
21 6 ; : 1-3, june 200 abstract: the low molecular weight heparin tinzaparin showed similar efficacy to enoxaparin sodium and adjusted-dose warfarin in preventing deep vein thrombosis dvt ; in patients undergoing total hip replacement, and to unfractionated heparin ufh ; in general surgery, but was more effective than warfarin in those undergoing total knee replacement and tipranavir.
This coloring guide serves as an extremely effective tool for students learning human anatomy through the act of coloring. The latest edition is organized by system and the information is reorganized so that text is found on the left-hand pages and the corresponding illustrations on right-hand pages.
Current found in the neurons after chronic exposure to nicotine is produced by up-regulated L-type VDCCs. Changes of pharmacological characteristics of nnAChRs after long-term exposure to nicotine--Previous studies have revealed that continuous activation of nnAChR with nicotine produces the increase of nnAChR number with desensitization 19, 36-39 ; . Therefore, whether and tobi.
The U.S. Food and Drug Administration, or comes for LMWHs are similar to those for inpaFDA, has approved three LMWHs: enoxaparin, tient heparin therapy, but at a lower cost. The dalteparin and ardeparin. The drugs tinzaparin analysis that produced this finding was conducted and danaparoid also have been approved. The by researchers in Canada and incorporated data FDA-approved agents are used for prophylaxis of from 300 patients randomly assigned to receive venous thromboembolism. Enoxaparin is the only twice-daily subcutaneous injections of enoxaone approved to treat nonQ-wave MIs and parin, administered primarily at home or through unstable angina and for prophylaxis before major a continuous infusion of heparin administered in surgery.8 None of the LMWHs are FDA-approved a hospital.13 The analysis considered costs related to treat atrial fibrillation or to prevent coagulato the provision of healthcare, patients' treattion on mechanical heart valves. As physicians ment-related travel time and work absences. The familiarize themselves with LMWHs, off-label overall mean treatment cost in Canadian dollars uses are becoming common for prophylaxis and per patient was , 323 for inpatient heparin treatment of thrombotic disorders during pregtherapy and , 278 for outpatient enoxaparin nancy, as adjunctive therapy for complicated pertherapy, a difference of , 045. When researchers cutaneous coronary interventions and as anticosubstituted U.S.dollar figures for hospitalization agulation therapy for mechanical prosthetic heart costs and the price of enoxaparin, they predicted valves to minimize the duration of hospitalizaa difference of , 750.13 tion. LMWHs are being used for offWe obtained cost data from label therapy for patients who have UIC's hospital pharmacy. The retail Cost-effectiveness and cost of 5 mg of warfarin was for mechanical heart valves and for convenience may play 30 tablets. The retail cost of 12 whom warfarin needs to be discontinued temporarily for surgery or syringes of 30 mg of enoxaparin major roles in dental procedures.8 was 5; our patient used a total choosing to use a There are two cases reported in low-molecular-weight of 12 syringes of 30 mg of enoxathe literature of LMWH treatment parin. The cost of hospitalization heparin instead of failure resulting in thrombosed room and bed ; was 0 per day. unfractionated prosthetic heart valves.9 In one The cost of one bag of IV heparin is heparin. case, a 29-year-old woman who had . On average one bag is used per an artificial mitral valve replaceday, but this can vary depending on ment had her warfarin therapy subthe patient's INR. The total cost of heparinization and hospitalization for one week is stituted with subcutaneous enoxaparin. She was , 510. Clearly, reducing the dosage of warfarin admitted in the 35th week of pregnancy after 32 to lower INR levels and coupling that with other weeks of treatment with enoxaparin, with acute management tools--such as tranexamic acid, pulmonary edema and severe hemodynamic absorbable gelatin sponges and sutures--is the decompensation. The patient underwent mitral valve replacement and a large, organized most cost-effective method. The use of an LMWH, thrombus was found on the old prosthesis. In the however, is more cost-effective and convenient second case, a 72-year-old patient who had an than hospitalization and heparinization. artificial aortic valve had a cerebral hemorrhage. CONCLUSION Treatment with warfarin was changed to enoxaparin. After 37 weeks of treatment, the patient The development of LMWH may affect the way presented with severe pulmonary congestion. dentists manage their patients who are receiving Urgent aortic valve replacement was performed, anticoagulation therapy and who require disconand the surgeons found that the artificial valve tinuation of warfarin and additional anticoagulawas severely obstructed with an organized tion while they wait for their INR to return to thrombus.9 Other literature, however, reports on acceptable levels. Some physicians may recomthe success of anticoagulation therapy with mend this alternative to their patients, and denLMWH for patients who have artificial heart tists should be aware of this possibility. The use valves.8 of LMWH is much more convenient for the Cost-effectiveness and convenience may play patient and more cost-effective than the use of major roles in choosing to use an LMWH instead unfractionated heparin and its associated requireof unfractionated heparin. Anticoagulant outment for hospitalization. No matter which form of!
LABELLING Curbs on Repackaging: Boehringer Ingelheim KG and others v Swingward Ltd; and v Dowelhurst Ltd Opinion of Advocate General Sharpston, 6 April 2006 ; The opening lines of Advocate General Sharpston's opinion in the twice-referred pharmaceutical, parallel imports case of Boehringer Ingelheim v Swingward; and v Dowelhurst cite the comments of Lord Justice Jacob when referring the case to the ECJ in his judgment of March 2004: "Sometimes I think the law may be losing a sense of reality in this area we are, after all, only considering the use of the owner's trade mark for his goods in perfect condition. The pickle the law has got into would, I think, astonish the average consumer." Mr Justice Laddie handed down two judgments on this case the first in February 2000, a second in February 2003, following a judgment of the European Court of Justice in April 2002. The Court of Appeal's decision followed in March 2004. Advocate General Sharpston has now delivered an opinion. Within the next few months, presumably, the ECJ will hand down judgment on the additional referred questions, before the Court of Appeal delivers its final decision. Lord Justice Jacob had a point. Background For those unfamiliar with this long-running saga, the issues are as follows. A pharmaceutical company places products on the market in one EU country. A parallel importer purchases product in that country usually from wholesalers ; and imports them into a second EU country. In order to comply with regulatory and marketing requirements of the country into which the products are imported, the parallel importer may need to alter the packaging. For example, inhalers imported into the UK need stickers with English language instructions; English language patient information leaflets are needed and so on. In some instances, the additional material will be added to the original box and a sticker applied to the outside of the original box detailing the marketing authorisation holder and other relevant and required information. In other instances, the importer will place the product into new packaging without unsightly stickers plastered on the outside overstickering is disliked by importers as they believe overstickered products are disliked by patients and hence the importers' customers ; . Sometimes, the importer will label the reboxed product with a generic description of the contents. Alternatively, the importer will label the reboxed product with the proprietary, trademarked name. The basic unstated assumption in relation to the last option was outlined by the Advocate General that refixing the originator's trade mark to the goods would, unless permitted by the paramount principle of free movement of goods within the EU, infringe the trade mark. BMS Conditions The conditions with which repackaging and reapplication of a trade mark should comply to avoid infringement were set out by the ECJ in Bristol-Myers Squibb v Paranova in 1996. The BMS conditions are as follows: 1. 2. 3. must be necessary to repackage to enable marketing of the product and avoid artificial partitioning of the market; There must be no effect on the original condition of the product e.g. blister packs must remain intact There must be clear identification of the original manufacturer and of the importer; The presentation must be non-damaging to the reputation of the trade mark the packaging must not be defective, of poor quality or untidy and tolcapone.
Maturity, apple maturity indices, preparing the orchard for harvest, mechanical and physiological disorders, bruising, storage optimum storage conditions, and apple varieties recommended for CA storage ; . In chapter 3, readers can find characterization of transport techniques and vehicles used in orchard and storage. Efficiency of the transport techniques and vehicles used in orchard, the methods of efficiency estimation in transport techniques, economic evaluation of transport technologies, costs and fuel consumption are submitted in chapter 4. In chapter 5 are described factors affecting damages in transport of apples, procedures of study effect of transport on apple damage, vibrations, fruit accelerations in bin as a consequence of vehicle vibrations, effect of vehicle type and driving speed on fruit damage, fruit position in the bin on the extent of damage and damage classification of apple. Physical methods for fruit quality evaluation, nondestructive measurements, physiological basis of texture, sensory evaluation of texture, mechanical properties related to fruit firmness, instrumental measurement of texture and firmness, are presented in chapter 6 "Fruit quality and texture". Quality properties of apple are presented in chapters 7. The results of the measurements of size, shape and weight, mechanical parameters of apple, apple firmness background for the study of firmness ; , friction between apple and flat surfaces are included in subchapters 7.1. to 7.5. In following subchapter 7.6. - color of apple and in subchapter 7.7., a nutritional value of apple is described. Transport requirements for apples product information, packaging, risk factors and loss prevention ; are presented in chapter 8. In chapter 9 are printed European Communities Regulations and Standards for Apples covering Commission Regulation EC ; No 85 2004 of 15 January 2004. In this regulation, Annex includes definition of produce, quality, sizing, tolerance, presentation, marking, while Appendix presents colouring, russeting, size criteria and the apple varieties, listed in table, which are classified according to their colouring, russeting and size criteria. The quality of fruits for direct consumption depends not only on correct technology of their production. In spite of the high quality of apples grown in Polish orchards, fruits offered to the consumer, due to incorrect handling, sometimes lack in their appearance Pieniek, 1981 ; . Proper utilization of fruits after harvest is according to that author the most important problem of Polish fruit farming. The first post-harvest operation that has an effect on the quality of fruits is their transport from the orchard to the storage facility. Rapid loading on refrigeration chambers and refrigeration of fruits within 3-4 days ; is one of the fundamental conditions of correct storage of apples in controlled atmosphere Lange, Ostrowski, 1992 ; . However, to ensure smooth loading of refrigeration chambers one has to deliver the harvested fruits to the storage facility rapidly and efficiently. This requires the use of efficient methods and means of transportation. Texture measurement has become widely accepted by horticultural industries as a critical indicator of non-visual aspects of quality. The ability to measure texture has.
CYCLOHEXIMIDE AND MOSSY FIBER SPROUTING REFERENCES BABB TL, KUPFER WR, PRETOURIUS JK, CRANDALL PH, AND LEVESQUE MF. Synaptic reorganization by mossy fibers in human epileptic fascia dentata. Neuroscience 42: 351363, 1991. BAZENET CE, RUANO AR, BROCKMAN JL, AND ANDERSON RA. The human erythrocyte contains two forms of phosphatidylinositol 4-phosphate 5-kinase which are differentially active towards membranes. J Biol Chem 365: 1801218022, 1990. BEN-ARI Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 14: 375 404, BENDOTTI C, PENDE M, GUGGLIEMETTI F, AND SAMANIN R. Cycloheximide inhibits kainic acid-induced GAP-43 mRNA in dentate granule cells. Neuroreport 7: 2539 2542, BUCKMASTER PS AND DUDEK FE. Network properties of the dentate gyrus in epileptic rats with hilar neuron loss and granule cell axon reorganization. J Neurophysiol 77: 26852696, 1997a. BUCKMASTER PS AND DUDEK FE. Neuron loss, granule cell reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J Comp Neurol 385: 404, BUCKMASTER PS AND DUDEK FE. In vivo intracellular analysis of granule cell axon reorganization in epileptic rats. J Neurophysiol 81: 712721, 1999. BUHL EH, OTIS TS, AND MODY I. Zinc induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. Science 271: 369 373, CALLAWAY EM AND KATZ LC. Photostimulation using caged glutamate reveals functional circuitry in living brain slices. Proc Natl Acad Sci USA 90: 76617665, 1993. CRONIN J, OBENAUS A, HOUSER CR, AND DUDEK FE. Electrophysiology of dentate granule cells after kainite-induce synaptic reorganization of the mossy fibers. Brain Res 573: 305310, 1992. DALVA MB AND KATZ LC. Rearrangements of synaptic connections in visual cortex revealed by laser photostimulation. Science 265: 255258, 1994. DUDEK FE AND SPITZ M. Hypothetical mechanisms for the cellular and neurophysiologic basis of secondary epileptogenesis: proposed role of synaptic reorganization. J Clin Neurophysiol 14: 90 101, HARDISON JL, OKAZAKI MM, AND NADLER JV. Modest increase in extracellular potassium unmasks effect of recurrent mossy fiber growth. J Neurophysiol 84: 2380 2389, HELLIER JL, PATRYLO PR, BUCKMASTER PS, AND DUDEK FE. Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 21: 73 84, HOUSER CR. Morphologic changes in the dentate gyrus in human temporal lobe epilepsy. In: The Dentate Gyrus and its Role in Seizures, edited by Ribak CE, Gall CM, and Mody I. Amsterdam: Elsevier, 1992, p. 223234. JONEC V AND WASTERLAIN CG. Effect of inhibitors of protein synthesis on the development of kindled seizures. Exp Neurol 66: 524 532, KATZ LC AND DALVA MB. Scanning laser photostimulation: a new approach for analyzing brain circuits. J Neurosci Methods 54: 205218, 1994. LONGO BM AND MELLO EAM. Blockade of pilocarpine- or kainate-induced mossy fiber sprouting by cyclohexamide does not prevent subsequent epileptogenesis in rats. Neurosci Lett 226: 163166, 1997. LONGO BM AND MELLO EAM. Supragranular mossy fiber sprouting is not necessary for spontaneous seizures in the intrahippocampal kainate model of epilepsy in the rat. Epilepsy Res 32: 172182, 1998. LONGO BM AND MELLO EAM. Effect of long-term spontaneous recurrent seizures or reinduction of status epilepticus on the development of supragranular mossy fiber sprouting. Epilepsy Res 36: 233241, 1999. LUNDBERG GA, JERGIL B, AND SUDLER R. Subcellular localization and enzymatic properties of rat liver phosphatidylinositol-4-phosphate kinase. Biochem Biophys Acta 846: 379 387, LYNCH M AND SUTULA T. Recurrent excitatory connectivity in the dentate gyrus of kindled and kainic acid-treated rats. J Neurophysiol 83: 693704, 2000. MAJERUS PW, NEUFELD EJ, AND WILSON DB. Production of phosphoinositidederived messengers. Cell 37: 701703, 1984. MCNAMARA JO. Cellular and molecular basis of epilepsy. J Neurosci 14: 34133425, 1994. MCNAMARA JO. Emerging insights into the genesis of epilepsy. Nature 24: 1522, 1999 and tolmetin.
To identify strategies to implement SCM through partnering in construction The local construction industry has been said to be resistance to change. Therefore, strategies need to be identified so that there will be at least a guidelines of how to overcome the obstacles in implementing SCM through partnering.
42 Table 5.2 cont. ; Causes of conditions by significance ; due to lymphatic filariasis Condition Causes Interaction with other causes Hydrocele14, 69 Main causes Direct normally clinical ; Bacteria enter tissues through entry lesions in the skin Indirect diet, exercise, alcohol and topotecan.
INJECTION, FOSCARNET SODIUM, PER 1000 MG INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 1 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 2 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 3 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 4 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 5 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 6 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 7 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 8 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 9 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 10 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, OVER 10 CC INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, 1 GRAM INJECTION, IMMUNE GLOBULIN, 10 MG INJECTION, RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN, INTRAVENOUS, 50 MG RESPIGAM ; INJECTION, GANCICLOVIR SODIUM, 500 MG INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG INJECTION, GATIFLOXACIN, 10 MG INJECTION, GLATIRAMER ACETATE, 20 MG COPAXONE ; INJECTION, GOLD SODIUM THIOMALATE, UP TO 50 MG INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG INJECTION, GONADORELIN HYDROCHLORIDE, PER 100 MCG INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG KYTRIL ; INJECTION, HALOPERIDOL, UP TO 5 MG INJECTION, HALOPERIDOL DECANOATE, PER 50 MG INJECTION, HEPARIN SODIUM, HEPARIN LOCK FLUSH ; , PER 10 UNITS INJECTION, HEPARIN SODIUM, PER 1000 UNITS INJECTION, DALTEPARIN SODIUM, PER 2500 IU INJECTION, ENOXAPARIN SODIUM, 10 MG LOVENOX ; INJECTION, FONDAPARINUX SODIUM, 0.5 MG INJECTION, TINZAPARIN SODIUM, 1000 IU INNOHEP ; INJECTION, HISTAMINE, UP TO 2.75 MG INJECTION, TETANUS IMMUNE GLOBULIN, HUMAN, UP TO 250 UNITS INJECTION, HYDROCORTISONE ACETATE, UP TO 25 MG INJECTION, HYDROCORTISONE SODIUM PHOSPHATE, UP TO 50 MG INJECTION, HYDROCORTISONE SODIUM SUCCINATE, UP TO 100 MG INJECTION, DIAZOXIDE, UP TO 300 MG INJECTION, IBUTILIDE FUMARATE, 1 MG INJECTION, INFLIXIMAB, 10 MG REMICADE ; INJECTION, IRON DEXTRAN, 50 MG INJECTION, IRON SUCROSE, 1 MG INJECTION, IMIGLUCERASE, PER UNIT CEREZYME ; INJECTION, DROPERIDOL, UP TO 5 MG INJECTION, PROPRANOLOL HCL, UP TO 1 MG INJECTION, DROPERIDOL AND FENTANYL CITRATE, UP TO 2 ML AMPULE INJECTION, INSULIN, PER 5 UNITS INSULIN FOR ADMINISTRATION THROUGH DME IE INSULIN PUMP ; PER 50 UNITS INJECTION, INTERFERON BETA-1A, 33 MCG, ADMINISTERED UNDER DIRECT PHYSICIAN INJECTION INTERFERON BETA-1B, 0.25 MG, ADMINISTERED UNDER DIRECT PHYSICIAN INJECTION, ITRACONAZOLE, 50 MG INJECTION, KANAMYCIN SULFATE, UP TO 500 MG INJECTION, KANAMYCIN SULFATE, UP TO 75 MG INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG INJECTION, CEPHALOTHIN SODIUM, UP TO 1 GRAM INJECTION, KUTAPRESSIN, UP TO 2 ML INJECTION, FUROSEMIDE, UP TO 20 MG INJECTION, LEUPROLIDE ACETATE FOR DEPOT SUSPENSION ; , PER 3.75 MG INJECTION, LEVOCARNITINE, PER 1 GM INJECTION, LEVOFLOXACIN, 250 MG INJECTION, LEVORPHANOL TARTRATE, UP TO 2 MG INJECTION, HYOSCYAMINE SULFATE, UP TO 0.25 MG INJECTION, CHLORDIAZEPOXIDE HCL, UP TO 100 MG INJECTION, LIDOCAINE HCL, 50 CC INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG INJECTION, LINCOMYCIN HCL, UP TO 300 MG INJECTION, LINEZOLID, 200 MG INJECTION, LORAZEPAM, 2 MG INJECTION, MANNITOL, 25% IN 50 ML INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG INJECTION, MEPERIDINE AND PROMETHAZINE HCL, UP TO 50 MG.
European markets France, Germany, Italy, Spain and the UK ; , about 2.7 million people suffer from Parkinson's. Of this group, 85% are over 65 years of age and toradol.
Trifluoroacetylation Method for Amines and Alcohols Materials: Methylene chloride Trifluoroacetic anhydride TFA ; Three milliliter screw-cap vials with silicone rubber inserts. Method: 1 ; Add to approximately 5mg analyte 2ml methylene chloride. 2 ; Add 0.2ml TFA, cap vial and heat 60C for 20 minutes. For polyols heat to 100C. Some polyols may require re-reaction. 3 ; Remove cap and evaporate to near dryness using dry nitrogen. Care should be taken when evaporating solvent not to vaporize sample. For highly volatile samples, evaporation to near dryness may result in loss of analyte. In cases such as this, a better sample work-up procedure would be: A. Using dry nitrogen in a fume hood, evaporate any remaining trifluoroacetic anhydride from sample methylene chloride and trifluoroacetic acid will still be present ; . B. Extract sample twice with a 5% wt v sodium bicarbonate solution. C. Pass methylene chloride layer through a bed of anhydrous sodium sulfate packed in Pasteur pipet ; to remove residual water. D. Sample is ready for injection. 4 ; Dissolve residue in 1ml methylene chloride. No further clean-up is necessary. Trimethylsilyl Ester Method for Carboxylic Acids Materials: BSTFA - N, O-bis trimethylsilyl ; trifluoroacetamide TMCS - Trimethylchlorosilane Three milliliter screw-cap vials with silicone rubber inserts. Method: 1 ; To approximately 1mg of analyte in a 3ml screwcap vial add 0.1ml BSTFA containing 1% TMCS v v ; . Add 0.1ml pyridine, cap vial and mix well.
0610320 BIOTECHNOLOGY TRADING COMPANY, INC. 0646889 0650036 CANON KABUSHIKI KAISHA ADVANCED TECHNOLOGY LABORATORIES, INC. THE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION 0667786 0692138 DEAKIN RESEARCH LIMITED ADVANCED ENERGY INDUSTRIES, INC. 0695349 0704125 Novozymes A S TELEFONAKTIEBOLAGET LM ERICSSON 0705851 0734263 ConocoPhillips Company THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 0750657 0752871 0759772 AMERICAN HIGH TEMP., INC. JLB, Inc., INNAPHARMA, INC. Deir, Thomas Pitre, John 0785521 UNITED PARCEL SERVICE OF AMERICA, INC. 0786177 0786962 Nokia Corporation BLAIRDEN PRECISION INSTRUMENTS, INC. 25 07 1996 and toremifene.
Table 3: Rate ratios RRs ; of acute myocardial infarction for current users of rofecoxib or celecoxib according to 2 measures of cumulative exposure calculated in the year preceding the index date Exposure No use Rofecoxib Prescriptions dispensed, no. 1 24 58 Days exposed, % 5.8 5.920.3 20.454.2 Celecoxib Prescriptions dispensed, no. 1 2-4 5-8 Days exposed, % 7.7 7.829.3 29.465.7 ; 0.96 0.731.26 ; 0.94 0.731.23 ; 0.99 0.761.27 ; 66 68 65 ; 0.88 0.671.16 ; 0.91 0.701.20 ; 1.02 0.811.29 ; 71 61 57 ; 1.32 0.991.76 ; 1.13 0.841.51 ; 1.02 0.751.38 ; 68 74 53 ; 1.24 0.951.61 ; 1.31 0.971.76 ; 0.96 0.701.32 ; Cases, no. 793 Controls, no. 16 680 Unadjusted RR 1.00 Adjusted RR * 95% CI ; 1.00 Reference.
PROGRAM BestPrep's Technology Integration Workshop is a four-day professional development experience for teachers interested in integrating technology and workplace skills into their curriculum. Teachers are asked to bring a previously taught curriculum unit that they would like to improve by developing a new approach for teaching the content. With the help of a Technology Integration Specialist, teachers develop at least one lesson or unit to use in their classroom during the next school year. As part of the program, teachers are connected with a Business Partner volunteer ; . They spend a half-day job shadowing their partner to better understand the skills students need after graduation. Teachers use this experience to develop more relevant curriculum that connects with real-world applications. In addition, teachers and business partners can meet throughout the school year to share, evaluate, modify and reflect upon their curriculum units. Each teacher who attends the Workshop contributes the curriculum they create to T-CELL TECH CORPS Electronic Lesson Library ; . T-CELL is maintained my BestPrep and available for all teachers who can view the lessons and then use in their classroom. BENEFITS Gain professional development activities and support; integrate technology applications into your curriculum that support content standards while promoting critical thinking and workplace skills. Infuse technology into a current lesson plan or unit and torsemide.
American journal of pharmaceutical education 2005; 69 4 ; article 72.
Storage and retention The container used to store a sample should not interact with the sampled material nor allow contamination. It should also protect the sample from light, air and moisture, as required by the storage directions for the pharmaceutical product or related material sampled. As a general rule the container should be sealed and preferably tamper-evident and tracleer and tinzaparin.
In the present study, we employed several experimental approaches to demonstrate greater basal vasoconstriction mediated via post-junctional a2-adrenoceptors in humans. In Protocol 1, we determined the forearm vasodilator responses to selective post-junctional a1-adrenoceptor blockade prazosin ; , followed by non-selective a-adrenoceptor blockade phentolamine ; . Expressed as a percentage of the total vasodilatation observed during complete post-junctional a-adrenoceptor blockade, the amount of vasoconstriction mediated via a1-adrenoceptors was 37 %, whereas that mediated via a2-adrenoceptors was 67 %. For this approach to be valid, we first needed to demonstrate complete a1-adrenoceptor blockade. The.
Miller SC. Detoxification. Departmental conference mental health ; . Wright Patterson USAF Medical Center. Wright Patterson Air Force Base, Ohio. 2002 May 3. Miller SC. Deployment: What it's like, how to cope, & what to bring. Departmental conference mental health ; . Wright Patterson USAF Medical Center. Wright Patterson Air Force Base, Ohio. 2002 April 4. Miller SC. Drug-facilitated sexual assault. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 2000 October 12. Miller SC. Rohypnol: date rape drug of the 90's. Departmental Conference addictions ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 2000 February. Miller SC. Intensive Addiction Services and cost analysis. Departmental offsite. Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 2000 January. Miller SC. Treatment planning. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1999 December. Miller SC. Closure of inpatient addictions unit: a quality improvement & business case analysis. JCAHO Presentation Hospital Conference. Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1999 October. Miller SC. Neurobiology of addiction disorders. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1999 May. Miller SC. Outpatient detoxification. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1999 March. Miller SC. Chronic effects of alcohol on human cognition. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1998 January. Miller SC. The development and use of the university of Toronto's narcotic withdrawal assessment tool: CINA. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1996 September. Miller SC. Substance abuse group therapy -- traditional and interpersonal models. Departmental conference mental health ; . Malcolm Grow USAF Medical Center. Andrews Air Force Base, Maryland. 1996 August and trandolapril.
Cheap tinzaparin
This work was supported by National Institutes of Health Grant GM031001 to E. F. Facilities for computer-assisted sequence analysis, DNA sequencing, and the synthesis of oligonucleotides were supported in part by General Clinical Research Center Grant M01 RR00833 and by the Sam and Rose Stein Charitable Trust. Portions of this research were carried out at the Stanford Synchrotron Radiation Laboratory SSRL ; , a national user facility operated by Stanford University on behalf of the United States Department of Energy, Office of Basic Energy Sciences. The SSRL Structural Molecular Biology Program is supported by the United States Department of Energy, Office of Biological and Environmental Research and by the National Center for Research Resources, Biomedical Technology Program, and NIGMS of the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. The atomic coordinates and structure factors code 1R9O ; have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ : rcsb ; . Both authors contributed equally to this work. To whom correspondence may be addressed: Dept. of Molecular Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., MB8, La Jolla, CA 92037. Tel.: 858-784-8738; Fax: 858-784-2857; E-mail: dave scripps . * To whom correspondence may be addressed: Dept. of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N. Torrey Pines Rd., MEM-255, La Jolla, CA 92037. Tel.: 858-784-7918; Fax: 858-784-7978; E-mail: johnson scripps . 1 The abbreviations used are: CYP or P450, a generic term for a cytochrome P450, with individual P450s identified using a numberletter-number format based on sequence relatedness; KPi, potassium.
02n3710table1 en.txt WHITE CIRCLE WITH LOWER RIGHT QUADRANT WHITE CIRCLE WITH UPPER RIGHT QUADRANT UPPER LEFT TRIANGLE UPPER RIGHT TRIANGLE LOWER LEFT TRIANGLE WHITE MEDIUM SQUARE BLACK MEDIUM SQUARE WHITE MEDIUM SMALL SQUARE BLACK MEDIUM SMALL SQUARE LOWER RIGHT TRIANGLE BLACK SUN WITH RAYS CLOUD UMBRELLA SNOWMAN COMET BLACK STAR WHITE STAR LIGHTNING THUNDERSTORM SUN ASCENDING NODE DESCENDING NODE CONJUNCTION OPPOSITION BLACK TELEPHONE WHITE TELEPHONE BALLOT BOX BALLOT BOX WITH CHECK BALLOT BOX WITH X SALTIRE UMBRELLA WITH RAIN DROPS HOT BEVERAGE WHITE SHOGI PIECE BLACK SHOGI PIECE REVERSED ROTATED FLORAL HEART BULLET BLACK LEFT POINTING INDEX BLACK RIGHT POINTING INDEX WHITE LEFT POINTING INDEX WHITE UP POINTING INDEX WHITE RIGHT POINTING INDEX WHITE DOWN POINTING INDEX SKULL AND CROSSBONES CAUTION SIGN RADIOACTIVE SIGN BIOHAZARD SIGN CADUCEUS ANKH ORTHODOX CROSS CHI RHO CROSS OF LORRAINE CROSS OF JERUSALEM STAR AND CRESCENT FARSI SYMBOL ADI SHAKTI HAMMER AND SICKLE PEACE SYMBOL YIN YANG WHEEL OF DHARMA WHITE FROWNING FACE WHITE SMILING FACE BLACK SMILING FACE WHITE SUN WITH RAYS FIRST QUARTER MOON LAST QUARTER MOON MERCURY FEMALE SIGN EARTH MALE SIGN Page 33.
Overall, the most common cause of hypothyroidism is the autoimmune disorder known as Hashimoto's thyroiditis see Hypothyroidism brochure ; . Hypothyroidism can occur during pregnancy due to the initial presentation of Hashimoto's thyroiditis, inadequate treatment of a woman already known to have hypothyroidism from a variety of causes, or over-treatment of a hyperthyroid woman with anti-thyroid medications. Approximately, 2.5% of women will have a slightly elevated TSH of greater than 6 and 0.4% will have a TSH greater than 10 during pregnancy.
Q. Should the dose of tinzaparin or enoxaparin be adjusted in obese patients ?.
Multi-dose vials 10, 000 anti-xa iu ml each ml of sterile solution contains tinzaparin sodium 10, 000 anti-xa iu and tipranavir.
Fanny packs, 2 carpenter's aprons, orange vests see below ; , facial tissues, walkie-talkies with extra batteries. Medical ID ankle or wrist bands similar to those used in hospitals ; to identify victims. Suggested signs are listed below.
Jumping, tumbling, dancing, the amount of spirit, and the desire to cheer became the determining factors of who should be on the 2004-2005 basketball cheerleading team. 24 girls tried out for the squad, but only 14 made this year's team. Girls who did football cheerleading agreed that the tryouts for basketball cheerleading were harder than football cheer tryouts. The coach, Johnna stated, "I looked for a lot of the same qualities as I did for football, but I think I was a lot harder on them. I want to have the best looking squad in Fairbanks." Stephanie Campbell and Sara Keyes two girls on the squad ; both said, " These tryouts were harder than football tryouts." Brittney Bunting, cheer captain, agreed that they were a little bit tougher than football, but that it was mainly because of the amount of girls trying out. Johnna had the girls trying out do the following things: 3 basic jumps, tumbling, fight.
EXERCISES, LESSON 3 INSTRUCTIONS: Answer the following exercises by marking the lettered response that best answers the exercise, by completing the incomplete statement, or by writing the answer in the space provided at the end of the exercise. After you have completed all these exercises, turn to "Solutions to Exercises" at the end of the lesson and check your answers. For each exercise answered incorrectly, reread the material referenced with the solution. 1. Microscopic examination of urinary sediment is clinically important because a. Such examination can quickly identify the constituents of calculi present in the sample. b. It can provide valuable information that enables the physician to diagnose renal and other abnormalities. c. Bacteria contaminating the sample can be identified in order that proper antibiotic therapy can be instituted by the physician.
Order tinzaparin
Replacement and after general surgery and for prevention of arterial thrombosis in patients with unstable angina Table 6 ; . No published studies have evaluated the efficacy of dalteparin in patients undergoing total knee replacement. Currently, tinzaparin has approval only for treatment of acute venous thromboembolism. In the absence of studies comparing different LMWH products, and when there have been no clinical trials that have assessed the efficacy of a specific LMWH product in patients with a specific indication, what dose of the LMWH should be used and what dosing regimen should be used? This is not a major problem for treatment of deep vein thrombosis because there have been published studies using enoxaparin FDA approved ; , tinzaparin FDA approved ; and dalteparin not FDA approved ; . However, for the indication of prophylaxis after total knee replacement there is little information to guide the selection of the optimal doses of tinzaparin or dalteparin. Tinzaparin has been studied in patients undergoing total knee replacement, with a dose of 75 anti-Xa IU kg daily. In the major study by Hull et al, this resulted in a lower incidence of venographically defined thrombosis but a higher incidence of bleeding compared to warfarin prophylaxis.33 This raises the possibility that a lower dose of tinzaparin may be optimal. Is the dose of dalteparin used to prevent thromboembolism after hip replacement surgery 5, 000 anti-Xa IU once daily ; the correct dose to use after knee replacement? No published studies provide the data needed to make an informed decision. A similar dilemma exists regarding the dosing of tinzaparin among patients with unstable angina. Essentially all of the studies that have assessed the use of LMWH in the prevention of venous thromboembolism for other conditions e.g., trauma, neurosurgery, medical patients ; have used enoxaparin. What is the appropriate dose of dalteparin and tinzaparin in these patients? Is the efficacy of LMWHs so robust all one has to do is simply select a dose proportionate to the dose of enoxaparin dose? Clearly the biggest challenge when making a therapeutic interchange is to determine the correct dose of a LMWH preparation. This is difficult when there are no.
MEWA plans are required to offer most of the same mandated benefits as other regulated insurance or HMO products. Except for those mandatory benefits, MEWA plans are not required to provide coverage of any other specific health service. ERISA Single Employer MEWAs, like other employer self-funded plans, are not subject to the North Carolina mandated benefits provisions, and thus are not required to offer any specific coverage in their plans unless mandated under federal law.
Buy tinzaparin
Membrane protein from liver mitochondrial membranes and 300 g of membrane protein from platelet membranes Fig. 4A ; . Photolabeling was therefore compared in aliquots of liver mitochondrial and platelet membranes containing similar amounts of MAO-B. [125I]AZIPI photoincorporated into a Mr 59, 000 peptide in liver mitochondrial membranes but not in platelet membranes Fig. 4B ; . The relative amounts of MAO-B in the two tissues were also determined using the MAO radioligand, [3H]pargyline Fig. 4C ; . Binding of this mechanismbased inhibitor indicated the presence of active enzyme in both platelet and liver mitochondrial membranes suggesting that the site of [125I]AZIPI photoincorporation on MAO-B is differentially accessible in these tissues. A similar lack of availability of the imidazoline binding doplatelet q, 500 g of membrane protein ; membranes in the presence of 10 M rauwolscine. Nonspecific binding was determined in the presence of 10 M cirazoline. At radioligand concentrations near the Kd, specific binding represented 90% of total binding in liver and 32% of total binding in platelets. Data are representative of two experiments performed in duplicate.
Cheap tinzaparin online
Efforts at designing more effective nucleoside analogs can include the notion that the rate of removal of these chain terminators by Pol may play a significant role in their overall toxicities. Ideally nucleoside analogs would be designed to mimic a "mismatch" so that they would be well discriminated against by Pol but also be removed at a fast rate because primer strand melting and or transfer would be faster. Furthermore, it appears that a better 3-OH mimic could aid in the actual rate of hydrolysis. It is noteworthy that each of the three most toxic nucleotide analogs, ddCTP, ddATP active metabolite of ddI ; and d4TTP, bind more tightly during polymerization than the corresponding natural nucleotides, and this tighter binding contributes significantly to their specificity constant governing incorporation leading to increased toxicity 15 ; . Moreover, these three analogs are the slowest to be excised by the proofreading exonuclease. It is reasonable to suppose that their greater affinity at the polymerase site reduces the rate and or equilibrium constants governing partitioning to the exonuclease site. If so, this one feature, tighter binding at the polymerase site, contributes doubly to their net toxicity by increasing rates of incorporation while decreasing rates of excision. Correlations of toxicity with structure imply that discrimination by the mitochondrial DNA polymerase requires a more!
Computed tomography of thorax revealed a well defined, huge heterogeneous mass occupying the left hemi thorax. Mass involved anterior segment of left upper lobe, lingular and left lower lobe. Mass was making acute angle with the chest wall and was running parallel to the left main bronchus. The bronchus per se was normal though pushed postero-medially.The density of mass ranged from 24 HU to Fig 2 ; . After I.V contrast, the mass showed heterogeneous enhancement with some well-defined focal nodules and linear bands of marked enhancement. There was no mediastinal lymphadenopathy or pleural effusion Fig 3.
Tinzaparin online
Abbreviated Prescribing Information for innohep tinzaparin sodium ; : Therapeutic indications: Treatment of deep vein thrombosis and pulmonary embolism. Prevention of deep vein thrombosis in patients undergoing general and orthopaedic surgery. Posology and method of administration: Administration is by subcutaneous injection. Treatment of DVT and PE: 175 anti-Xa IU kg body weight once daily for at least 6 days and until adequate oral anticoagulation is established. Prevention of DVT in patients undergoing general surgery: 3, 500 anti-Xa IU 2 hours before surgery and then once-daily for 710 days. Prevention of DVT in patients undergoing orthopaedic surgery: 4, 500 anti-Xa IU 12 hours before surgery and then once daily or 50 anti-Xa IU kg body weight 2 hours before surgery and then once-daily for 7-10 days. Contraindications: Known hypersensitivity to constituents. Current or history of heparin induced thrombocytopenia. Other contraindications are generalised or local haemorrhagic tendency, including uncontrolled severe hypertension, severe liver insufficiency, acute or subacute septic endocarditis, intracranial haemorrhage or injuries and operations on the central nervous system, eyes and ears, and in women with abortus imminens. Special precautions: innohep should be given with caution to patients with renal or hepatic insufficiency. In such cases a dose reduction should be considered. innohep should not be administered by intramuscular injection due to risk of local haematoma formation. Due to the content of sodium metabisulphite, innohep 20, 000 anti-Xa IU ml should not be used in patients with asthma and hypersensitivity to sulphites. Patients receiving innohep concurrently with spinal or epidural anaesthesia should be closely monitored for signs or symptoms of neurological injury. As a precaution, platelets counts should be determined prior to the start of treatment, and, subsequently, twice weekly for the duration of treatment. Some formulations of innohep contain the preservative benzyl alcohol. These formulations should not be used in newborn babies. Interactions: The anticoagulant effect of innohep may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system, e.g. salicylates, non-steroidal anti-inflammatory drugs, vitamin K antagonists and dextrans. Use during pregnancy and lactation: Only limited clinical documentation is available on innohep so far, and there has been no evidence of adverse reactions in animal models. As a precaution innohep should not be used in pregnancy unless no safer alternative is available. It is not known whether innohep is excreted in breast milk. Undesirable effects: innohep is safe with regard to bleeding risks, when applied at the doses recommended, provided that patients with increased bleeding potential bleeding disorders, severe thrombocytopenia ; are excluded or treated with special care. Minor adverse effects, such as wound haematomas and injection site haematomas, may occur. As to heparin, a transient increase in aminotransferase levels is frequently seen. Cessation of treatment is usually not required. Extremely rare reactions: Systemic allergic reactions, such as thrombocytopenia. Priapism and skin necrosis have been reported in only a few cases. Overdosage: An overdose of innohep may be complicated by haemorrhage. The effect of innohep can be reversed by intravenous administration of 1% protamine sulphate solution . The dose of protamine sulphate required per neutralisation should be accurately determined by titrating with the plasma of the patient. As a rule, 1 mg of protamine sulphate neutralises the effect of 100 anti-Xa IU of tinzaparin. Presentations: Vials of 2 ml: Tinzaparin sodium 10, 000 anti-Xa IU ml, preserved with benzyl alcohol. Tinzaparin sodium 20, 000 anti-Xa IU ml, preserved with benzyl alcohol, stabilized with sodium metabisulphite. Syringe of 0.25 ml, 0.35 ml or 0.45 ml: Tinzaparin sodium 10, 000 anti-Xa IU ml Graduated syringe of 0.50 ml, 0.70 ml or 0.90 ml: Tinzaparin sodium 20, 000 anti-Xa IU ml stabilized with sodium metabisulphite.
Remember how the self defense experts would tell you to place your keys between your fingers and punch? Now there is something much better and more effective. Carry the HEART ATTACK on your key chain and be ready to protect yourself anytime. The Heart Attack is small 3.5 inches long ; and made of tough plastic. Hold it between your fingers and punch! Attackers beware! HA-1 .95.
|
|
